ICLR - アイコン （ICON plc） アイコンICLRのチャート
ICLRの企業情報
| symbol | ICLR |
|---|---|
| 会社名 | Icon Plc （アイコン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Commercial Physical_Biological Resarch |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイコン(ICON public limited company)は医薬品開発業務受託機関(CRO)であり、世界的規模で医薬品、バイオテクノロジー及び医療機器業界向けに受託開発サービスの提供に従事する。同社はプログラムの戦略的開発、管理および分析に取り組み、化合物選択から、第Ⅰ相試験から第Ⅳ相試験までの臨床試験までを含む全段階の臨床開発プロセスを支援する。ICON中央研究所（ICON Central Laboratories）が提供する特定のサービスはサンプル分析、安全性試験、微生物学、カスタムフローサイトメトリー、テスト結果の電子送信、およびバイオマーカーの開発を含む。平成24年2月28日、同社はPriceSpective LLC (PriceSpective)を買収した。平成24年2月15日、同社はBeijingWits Medical Limited (BeijingWits)を買収した。平成25年2月15日、同社はCross Country Healthcare Inc.の臨床試験サービス事業部を買収した。 アイコンは、アイルランドの医薬品開発業務受託会社。医薬品、バイオテクノロジ―、医療機器産業に開発業務受託サ―ビスを提供する。主に、化合物の選択から第I～IV相臨 床試験に至るまでの臨床開発を支援するプログラムの開発、管理、分析を行う。本社は、アイルランドのダブリン。 icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end' pharmacovigilance service provider and this includes post marketing surveillance activities too. |
| 本社所在地 | South County Business Park Leopardstown Dublin 18 IRL |
| 代表者氏名 | Ciaran Murray Ciaran Murray |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +353 1-291-2000 |
| 設立年月日 | 1990年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1998年 |
| 従業員数 | 13250人 |
| url | www.iconplc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/iclr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 427.20200 |
| 終値（lastsale） | 147.58 |
| 時価総額（marketcap） | 8017706907.02 |
| 時価総額 | 時価総額（百万ドル） 7724.336 |
| 売上高 | 売上高（百万ドル） 2157.197 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7700.414 |
| 当期純利益 | 当期純利益（百万ドル） 303.42800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ICON PLC revenues increased 46% to $1.26B. Net income increased 10% to $150M. Revenues reflect Reimbursable expenses decrease from $306.9M to $0K Revenue increase of 8% to $1.26B. Net income was partially offset by Depreciation and amortization increase of 18% to $33.9M (expense) Restructuring increase of 61% to $12.5M (expense) Interest expense increase of 12% to $7.1M (expense). |
ICLRのテクニカル分析
ICLRのニュース
ICON PLC: Disconnect From Fundamentals, Unfairly Punished 2023/06/03 03:58:15 Seeking Alpha
ICON PLC shares set higher lows in June, and the company presents strong fundamentals and economic earnings for shareholders. See why I rate ICLR stock a Buy.
Preclinical Assets Market to See Booming Growth 2023-2030 | Eurofins Scientific, ICON plc, Domainex, AmplifyBio, IQVIA 2023/06/02 09:28:43 EIN News Lung Cancer
Global preclinical assets market size is valued at US$ 5,250.2 million in 2023 and is expected to witness a CAGR of 7.5% over the forecast period (2023 – 2030) BURLINGAME, CALIFORNIA, UNITED STATES, June 2, 2023 /EINPresswire.com/ -- " …
Poolbeg Pharma PLC Announces Board Appointment 2023/05/24 06:00:00 Accesswire
LONDON, UK / ACCESSWIRE / May 24, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ''Poolbeg'' or the ''Company''), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee. Professor Buckley is the former Chief Medical Officer of ICON plc, a medical graduate of University College Cork and a doctoral graduate in Biochemistry in the Faculty of Medicine at Oxford University. Prof Buckley has advised Poolbeg since inception and has deep experience in metabolic diseases including over 40 years'' experience in clinical practice as a Consultant Physician in endocrinology, diabetes and in academic clinical pharmacology. Brendan was a member of the Board of Directors of the Irish Medicines Board (now the Health Products Regulatory Authority), chairing its statutory Advisory Committee for Human Medicines.
ICON plc: ICON releases its 2022 ICON Cares ESG Report 2023/05/16 10:06:00 Finanz Nachrichten
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. The compa…
Pediatric Clinical Trials Market Will Show the Highest Growth Rates & Incredible Demand By 2030: ICON plc, Pfizer, Inc 2023/04/28 07:18:41 EIN News Lung Cancer
BURLINGAME, CALIFORNIA, UNITED STATES, April 28, 2023 /EINPresswire.com/ -- : Coherent market insights recently published a comprehensive business research report on the “Pediatric Clinical …
Pediatric Clinical Trials Market Will Show the Highest Growth Rates & Incredible Demand By 2030: ICON plc, Pfizer, Inc 2023/04/28 07:18:41 EIN News Lung Cancer
BURLINGAME, CALIFORNIA, UNITED STATES, April 28, 2023 /EINPresswire.com/ -- : Coherent market insights recently published a comprehensive business research report on the “Pediatric Clinical …
Iqvia, Icon lag contract research rivals after Q1 earnings 2023/04/27 18:33:00 Seeking Alpha
IQVIA Holdings (IQV) and ICON Public Limited (ICLR) led decliners in the contract research space Thursday after reiterating the guidance despite Q1 beat. Read more here.
ICON Public Limited Company (ICLR) Q1 2023 Earnings Call Transcript 2023/04/27 18:22:10 Seeking Alpha
ICON Public Limited Company (NASDAQ:NASDAQ:ICLR) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ETCompany ParticipantsKate Haven - VP of IRSteve Cutler - CEOBrendan Brennan -…
Icon PLC: Q1 Earnings Snapshot 2023/04/26 21:43:55 WTOP
DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported first-quarter net income of $116.7 million. On a per-share…
ICON plc: ICON Reports First Quarter 2023 Results 2023/04/26 20:36:00 Finanz Nachrichten
Highlights Net business wins in the quarter of $2,415 million; a net book to bill of 1.22. Closing backlog of $21.2 billion, an increase of 2.4% on quarter four 2022 or an increase of 8.4% on quar…
ICON plc to Present at the 2022 Wells Fargo Healthcare Conference 2022/08/31 20:15:00 Business Wire
DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the 2022 Wells Fargo Healthcare Conference
Baron Funds Expects Huge Growth in ICON Public Limited Company (ICLR) 2022/08/30 18:28:25 Insider Monkey
Baron Funds, an asset management company, released its “Baron Asset Fund” investor letter. You can download a copy of the same here. In the second quarter, the fund fell 21.09%. However, the firm believes that the fund is positioned to perform well in the current market concerns of recession and inflation. In addition, you can […]
Sectoral Asset Management Inc Buys 2, Sells 3 in 2nd Quarter 2022/08/15 23:00:43 GuruFocus
Related Stocks: OCDX , ICLR , LNTH , HCAT , TMO ,
3 Explosive Growth Stocks to Keep on Your Radar 2022/08/12 16:01:09 InvestorPlace
The search for growth stocks is always on for many investors. While sentiment for many high-growth stocks is at rock-bottom levels, many growth investors now have opportunities available at much more attractive prices. This first half of 2022 was the worst year in a very long time in the stock market. This was even more true for growth stocks. In the second quarter alone, the Nasdaq saw a decline of more than 22%. That’s the worst level since the Great Recession. However, if history is our guide, these declines don’t last forever. At some point, buyers come out of the woodwork to load up on these stocks. Accordingly, the search for quality among explosive growth stocks is on. The following list includes three explosive growth stocks I think have quality attributes long-term investors may want to consider. For those looking to buy the dip, here are three great options to consider. BKNG Booking Holdings $2,091.57 ICLR Icon $240.21 AMZN Amazon $141.23 Booking Holdings (BKNG) Source: Andrey Solovev / Shutterstock Still down approximately 15% year-to-date, Booking Holdings (NASDAQ: BKNG ) remains a high-conviction pick of many top analysts right now.